This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health and nephrology markets. The company used advances in cellular and molecular biology to develop two of the biotech industry’s earliest and most successful drugs, Epogen (anemia) and Neupogen (white blood cell stimulant). Amgen successfully launched two next-generation products, Aranesp and Neulasta. Meanwhile, the acquisition of Immunex Corporation gave Amgen access to the multi-blockbuster drug, Enbrel. However, all these older drugs are facing declining sales due to biosimilar or branded competition, which is being somewhat offset by its newer blockbuster drugs like Prolia/Xgeva
Biogen (BIIB) Q3 Earnings Coming Up: What's in the Cards?
by Zacks Equity Research
On the third-quarter call, investor focus will be on the impact of Roche's newly launched drug, Ocrevus on Biogen's (BIIB) MS franchise and Spinraza's performance.
AMGN or ILMN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
AMGN vs. ILMN: Which Stock Is the Better Value Option?
Top Ranked Income Stocks to Buy for October 19th
by Zacks Equity Research
Here are three stocks with buy rank and strong income characteristics for investors to consider today, October 19th:
Novartis Reports Positive Long-Term Data From Cosentyx Trials
by Zacks Equity Research
Novartis (NVS) announces encouraging five-year data from late-stage studies on Cosentyx for psoriatic arthritis and ankylosing spondylitis indications.
Can Allergan's Key Drugs, Solid Pipeline Abate Generic Woes?
by Zacks Equity Research
Allergan (AGN) is facing loss of exclusivity for many blockbuster products. However, drugs like Botox/Linzess, new drugs and cost cuts can shield it from potential sales drop.
Roche Announces Positive Data on Breast Cancer Drug Kadcyla
by Zacks Equity Research
Roche's (RHHBY) breast cancer drug Kadcyla, in a late-stage study in patients suffering from HER2-positive eBCmet, met its goal.
Immune Design to Halt Cancer Vaccine Program, Shares Plunge
by Zacks Equity Research
Immune Design (IMDZ) to discontinue the CMB305 cancer vaccine program and focus on the development of its lymphoma therapy, G100.
Top Ranked Income Stocks to Buy for October 15th
by Zacks Equity Research
Here are four stocks with buy rank and strong income characteristics for investors to consider today, October 15th:
AbbVie Settles With Novartis to Delay Humira Biosimilar in US
by Zacks Equity Research
AbbVie (ABBV) strikes a deal with Sandoz, the generic arm of Novartis, to launch its biosimilar Humira in the United States on Sep 30, 2023.
J&J (JNJ) to Set the Ball Rolling for Pharma Q3 Earnings
by Zacks Equity Research
The positive trend seen in J&J's (JNJ) pharma segment sales is likely to continue in the third quarter.
Top Ranked Income Stocks to Buy for October 11th
by Zacks Equity Research
Here are four stocks with buy rank and strong income characteristics for investors to consider today, October 11th:
Roche (RHHBY) Presents Encouraging Data on MS Drug Ocrevus
by Zacks Equity Research
Roche's (RHHBY) MS drug Ocrevus lowers disability progression over five years in relapsing/primary progressive multiple sclerosis with an early initiation of treatment.
Tilary Buys Alef Biotechnology to Build Base in Latin America
by Zacks Equity Research
Tilary (TLRY) acquires import and distribution partner, Alef Biotechnology to strengthen its base in Latin America.
FDA Sets Action Date for Recro's Pain Management Candidate
by Zacks Equity Research
The FDA has set an action date of Mar 24, 2019 for Recro's lead product candidate, intravenous (IV) meloxicam, for the management of moderate to severe pain.
Bausch's Bryhali Gets Tentative FDA Nod for Plaque Psoriasis
by Zacks Equity Research
Bausch receives tentative FDA approval for the NDA for Bryhali (halobetasol propionate) Lotion, 0.01%, for the topical treatment of plaque psoriasis in adult patients.
Kala Pharmaceuticals (KALA) Catches Eye: Stock Jumps 7.4%
by Zacks Equity Research
Kala Pharmaceuticals (KALA) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
5 Reasons Why Investors Should Bet on Merck (MRK) Stock
by Zacks Equity Research
Here are some reasons why investors may consider putting their money into Merck (MRK) stock.
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
Roche's Hemlibra Receives FDA Approval for Label Expansion
by Zacks Equity Research
Roche (RHHBY) obtains the FDA approval for the label expansion of Hemlibra for the treatment of adults and children suffering haemophilia A without factor VIII inhibitors.
Roche (RHHBY) Presents Encouraging Data on SMA Drug Risdiplam
by Zacks Equity Research
Roche (RHHBY) reports encouraging data from two pivotal studies -- FIREFISH and SUNFISH -- on risdiplam for the treatment of Spinal Muscular Atrophy.
Amgen Gets FDA Nod for Once-Weekly Regimen of Kyprolis Combo
by Zacks Equity Research
Amgen (AMGN) gains an FDA approval for its sNDA with respect to a once-weekly dosing option of its multiple myeloma drug Kyprolis (70 mg/m2) combined with dexamethasone (Kd).
Biotech Stock Roundup: ALXN on Acquisition Spree, FDA Nod for REGN, AMGN Drugs
by Zacks Equity Research
The biotech sector grabs headlines this week with FDA approvals plus licensing and acquisition pacts.
Merck & Other Pharma Players Await FDA Decisions in October
by Kinjel Shah
FDA grants approval to 41 new treatments till the end of September.
The Zacks Analyst Blog Highlights: Chevron, Amgen, Thermo Fisher, Estee Lauder and Delta Air Lines
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Chevron, Amgen, Thermo Fisher, Estee Lauder and Delta Air Lines
Dr. Reddy's Sells Antibiotic Production Hub to UAE Drugmaker
by Zacks Equity Research
Dr. Reddy's (RDY) divests its Bristol, TN-based antibiotic manufacturing site and related assets to an Abu Dhabi-based company.